7766-23-6

Basic information

• Product Name: 3-BROMO-2-METHYLPHENOL
• Synonyms: 3-BROMO-2-METHYLPHENOL;2-Bromo-6-hydroxytoluene, 3-Bromo-o-cresol;2-Methyl-3-broMophenol;Phenol, 3-bromo-2-methyl-
• CAS NO: 7766-23-6
• Molecular Formula: C₇H₇BrO
• Molecular Weight: 187.04
• Mol File: 7766-23-6.mol

Chemical Properties

• Melting Point: 95°C
• Boiling Point: 220.79°C (rough estimate)
• Appearance: /
• Density: 1.3839 (rough estimate)
• Refractive Index: 1.5772 (estimate)
• Storage Temp.: Inert atmosphere,Room Temperature
• Solubility: Chloroform (Slightly), Methanol (Slightly)
• PKA: 9.35±0.10(Predicted)
• CAS DataBase Reference: 3-BROMO-2-METHYLPHENOL(CAS DataBase Reference)
• NIST Chemistry Reference: 3-BROMO-2-METHYLPHENOL(7766-23-6)
• EPA Substance Registry System: 3-BROMO-2-METHYLPHENOL(7766-23-6)

Safety Data

• Hazardous Substances Data: 7766-23-6(Hazardous Substances Data)

Usage

Uses

Used in Personal Care and Healthcare Industries:
3-Bromo-2-methylphenol is used as a disinfectant and antiseptic for its potent antimicrobial capabilities, ensuring cleanliness and preventing infections in personal care products and healthcare settings.
Used in Pharmaceutical Synthesis:
3-Bromo-2-methylphenol serves as a key intermediate in the synthesis of various pharmaceuticals, contributing to the development of new medications and therapies.
Used in Agrochemical Production:
3-BROMO-2-METHYLPHENOL is also utilized in the production of agrochemicals, playing a role in the creation of pesticides and other agricultural products to protect crops and enhance yields.
Used in Research and Laboratory Settings:
3-Bromo-2-methylphenol is employed as a reagent in organic synthesis, facilitating important research and development activities in scientific laboratories. Its synthetic capabilities make it an essential tool for creating new chemical compounds and advancing chemical knowledge.

Upstream product

• 55289-35-5 2-bromo-6-nitrotoluene 
• 69321-60-4 2,6-dibromotoluene 
• 603-83-8 3-nitro-o-tolylamine 
• 95-46-5 2-methylphenyl bromide 
• 95-48-7 ortho-cresol 
• 55289-36-6 3-bromo-2-methylaniline 

Downstream Products

• 52045-21-3 3,6-dibromo-2-methyl-phenol 
• 55289-38-8 3,4,6-tribromo-2-methyl-phenol 
• 573693-08-0 2-bromo-4-methoxy-3-methyl-phenylamine 
• 573693-11-5 2-bromo-4-methoxy-3-methyl-1-nitro-benzene 
• 573693-12-6 3-(2-bromo-4-methoxy-3-methyl-phenylamino)-4-methoxy-benzoic acid methyl ester 
• 573693-14-8 8-bromo-1,6-bis-(tert-butyl-diphenyl-silanyloxy)-7-methyl-9H-carbazole-4-carboxylic acid methyl ester 
• 573693-16-0 [1,6-bis-(tert-butyl-diphenyl-silanyloxy)-8-(2,5-dimethyl-hex-1-enyl)-7-methyl-9H-carbazol-4-yl]-methanol 
• 573693-15-9 1,6-bis-(tert-butyl-diphenyl-silanyloxy)-8-(2,5-dimethyl-hex-1-enyl)-7-methyl-9H-carbazole-4-carboxylic acid methyl ester 
• 1430846-22-2 1-(3-bromo-2-methylphenoxy)tricyclo[3.3.1.1^3,7]decane 
• 1329991-97-0 C₉H₁₀BrIO 
• 1329991-96-9 C₉H₁₁BrO₂ 
• 93710-55-5 2-(2-bromo-6-methoxyphenyl)acetonitrile 
• 126712-05-8 1-bromo-2-(bromomethyl)-3-methoxybenzene 
• 1283143-05-4 2-((2S)-1-(4-(2'-fluoro-5'-methoxy-2-methylbiphenyl-3-yloxy)phenyl)pyrrolidin-2-yl)acetic acid trifluoroacetic acid salt 

Relevant articles and documents

Discovery of novel small-molecule inhibitors of pd-1/pd-l1 interaction via structural simplification strategy

Blockade of the programmed cell death 1 (PD-1)/programmed cell death-ligand 1 (PD-L1) interaction is currently the focus in the field of cancer immunotherapy, and so far, several monoclonal antibodies (mAbs) have achieved encouraging outcomes in cancer tr

Novel biphenyl derivative as well as preparation method and medical application thereof

The invention relates to the field of medicinal chemistry, and discloses biphenyl derivatives with PD-1/PD-L1 inhibitory activity as well as a preparation method and application of the biphenyl derivatives. The invention further discloses a composition containing the biphenyl derivative with the PD-1/PD-L1 inhibitory activity or the pharmaceutically acceptable salt of the biphenyl derivative and a pharmaceutically acceptable carrier of the biphenyl derivative, and application of the biphenyl derivative in preparation of a PD-1/PD-L1 inhibitor. The compound can be used for treating tumors.

Discovery of 1,3,4-oxadiazole derivatives as potential antitumor agents inhibiting the programmed cell death-1/programmed cell death-ligand 1 interaction

Inhibition of the programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) interaction by small-molecule inhibitors is emerging cancer immunotherapy. A series of novel 1,3,4-oxadiazole derivatives were designed, synthesized, and evaluated for

Method for synthesizing 3 - halogen -2 -alkyl phenol

The invention discloses a synthesis method of 3 -halo -2 - alkyl phenol, and belongs to the technical field of organic synthesis. At 2, 6 - dihaloalkylbenzene is used as starting material, nucleophilic substitution with dibenzyl alcohol in the presence of an inorganic base followed Pd / C hydrodebenzylation or Grignard exchange with magnesium metal in the presence of n-butylbromide/chloride followed by air/oxygen to give 3 - halo -2 - alkylphenols. The method has the advantages of high regioselectivity, good yield, simple operation process and the like, and the product purity can reach 99.5% or more.

Divergent Enantioselective Synthesis of (Nor)illudalane Sesquiterpenes via Pd0-Catalyzed Asymmetric C(sp3)-H Activation

A divergent enantioselective synthesis of (nor)illudalane sesquiterpenes was designed by using a Pd0-catalyzed asymmetric C(sp3)-H arylation as a key step to control the isolated, highly symmetric quaternary stereocenter of the targe

Total Synthesis of (Nor)illudalane Sesquiterpenes Based on a C(sp3)-H Activation Strategy

Three (nor)illudalane sesquiterpenes were synthesized from a common intermediate in racemic and enantioenriched forms using Pd0-catalyzed C(sp3)-H arylation as a key step. The configuration of the isolated, highly symmetric quaternar

Total Synthesis of Marine Alkaloid Hyellazole and its Derivatives

The total synthesis of the naturally occurring marine alkaloids hyellazole and chlorohyellazole was attempted from the corresponding easily accessible 2-methyl-1-ketotetrahydrocarbazoles obtained through the Japp–Klingemann reaction, followed by Fischer indole cyclization and subsequent Grignard coupling with phenylmagnesium bromide. Grignard coupling with 2-methyl-1-ketotetrahydrocarbazole unfortunately led directly to 2-methyl-1-phenylcarbazole through dehydration followed by aromatization through aerial oxidation, but application of the same reaction conditions to 6-chloro-2-methyl-2,3,4,9-tetrahydro-1H-carbazol-1-one, with careful treatment, led to the isolation of 6-chloro-2-methyl-1-phenyl-4,9-dihydro-3H-carbazole. However, selenium dioxide oxidation of this dihydrochloro derivative led to the formation of 6-chloro-2-methyl-1-phenyl-9H-carbazole. A different route was then adopted: a suitably substituted aromatic amine was used to establish the substitution pattern of the required carbazole derivative with a bromo group at C-1, and the required phenyl group at the 1-postion was then attached through Suzuki–Miyaura cross-coupling to furnish hyellazole.

Axially Chiral Dibenzazepinones by a Palladium(0)-Catalyzed Atropo-enantioselective C?H Arylation

Atropo-enantioselective C?H functionalization reactions are largely limited to the dynamic kinetic resolution of biaryl substrates through the introduction of steric bulk proximal to the axis of chirality. Reported herein is a highly atropo-enantioselective palladium(0)-catalyzed methodology that forges the axis of chirality during the C?H functionalization process, enabling the synthesis of axially chiral dibenzazepinones. Computational investigations support experimentally determined racemization barriers, while also indicating C?H functionalization proceeds by an enantio-determining CMD to yield configurationally stable eight-membered palladacycles.

Propionic Acid Derivatives and Methods of Use Thereof

Provided herein are compounds and pharmaceutical compositions of formula I where R1, R2, R3, R4, R5 and R6 are as described herein. Also provided pharmaceutically acceptable salts or stereoisomers of these compounds. In addition methods are provided for inhibiting the binding of an integrin to treat various pathophysiological conditions.

Discovery of Pyrrolidine-Containing GPR40 Agonists: Stereochemistry Effects a Change in Binding Mode

A novel series of pyrrolidine-containing GPR40 agonists is described as a potential treatment for type 2 diabetes. The initial pyrrolidine hit was modified by moving the position of the carboxylic acid, a key pharmacophore for GPR40. Addition of a 4-cis-CF3 to the pyrrolidine improves the human GPR40 binding Ki and agonist efficacy. After further optimization, the discovery of a minor enantiomeric impurity with agonist activity led to the finding that enantiomers (R,R)-68 and (S,S)-68 have differential effects on the radioligand used for the binding assay, with (R,R)-68 potentiating the radioligand and (S,S)-68 displacing the radioligand. Compound (R,R)-68 activates both Gq-coupled intracellular Ca2+ flux and Gs-coupled cAMP accumulation. This signaling bias results in a dual mechanism of action for compound (R,R)-68, demonstrating glucose-dependent insulin and GLP-1 secretion in vitro. In vivo, compound (R,R)-68 significantly lowers plasma glucose levels in mice during an oral glucose challenge, encouraging further development of the series.